A randomized, double-blind, single-dose study to assess bioequivalence of MB02 biosimilar after manufacturing iteration and reference bevacizumab.

Schwabe, C; Cole, A; Espigares-Correa, A; Beydon, M E; Florez-Igual, A; Queiruga-Parada, J

Schwabe, C; Cole, A; Espigares-Correa, A; Beydon, M E; Florez-Igual, A; Queiruga-Parada, J.

Afiliación

Schwabe C; Auckland Clinical Studies Ltd, Auckland, New Zealand.
Cole A; Christchurch Clinical Studies Trust Ltd, Christchurch, New Zealand.
Espigares-Correa A; Medical Department, mAbxience Research S.L., Madrid, Spain.
Beydon ME; Research and Development Department, mAbxience Research S.L., Madrid, Spain.
Florez-Igual A; Medical Department, mAbxience Research S.L., Madrid, Spain.
Queiruga-Parada J; Medical Department, mAbxience Research S.L., Madrid, Spain.

Pharmacol Res Perspect ; 11(2): e01070, 2023 04.

Article en En | MEDLINE | ID: mdl-36914963

Asunto(s)

Biosimilares Farmacéuticos; Humanos; Masculino; Bevacizumab/efectos adversos; Bevacizumab/farmacocinética; Equivalencia Terapéutica; Administración Intravenosa; Método Doble Ciego

Palabras clave

MB02; bevacizumab; biosimilar; clinical trial; pharmacokinetics; safety

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Biosimilares Farmacéuticos Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans / Male Idioma: En Revista: Pharmacol Res Perspect Año: 2023 Tipo del documento: Article País de afiliación: Nueva Zelanda

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google